title: The folic acid metabolite L-5-methyltetrahydrofolate effectively reduces total serum homocysteine level in orthotopic liver transplant recipients: a double-blind placebo-controlled study.
abstract: OBJECTIVE
  Hyperhomocysteinemia is a described risk factor of cardiovascular diseases. The aim of this study was the treatment of hyperhomocysteinemia in liver transplant recipients with L-5-methyltetrahydrofolate (L-5-MTHF; 1 mg) vs folic acid (1 mg) vs placebo in a double-blind placebo-controlled study and to compare the relative responsiveness of these patients to L-5-MTHF and folic acid.
  
  
  METHODS
  Patients were recruited from Hepatology-Transplantation-Unit at Johann Wolfgang Goethe-University, Frankfurt. Sixty patients were included in this study and 12 patients dropped out for different reasons. The patients were treated over 8 weeks with supplemental L-5-MTHF or folic acid or placebo. Serum homocysteine (HCY) was analyzed with high-performance liquid chromatography (HPLC) beside routine lab tests.
  
  
  RESULTS
  We observed only a significant decrease of total serum HCY in the L-5-MTHF group during the study period (at week 0: 15+/-7.7 microM; after 8 weeks treatment: 9.41+/-2.6 microM, P<0.001). There was no significant decrease of total serum HCY neither in the folic acid group nor in the placebo group.
  
  
  CONCLUSIONS
  The effects of L-5-MTHF are significantly more potent than folic acid itself. Therefore, lowering serum HCY in liver transplant recipients is effective with L-5-MTHF.
authors.affiliation: 1st Department of Internal Medicine and Gastroenterology, Johann Wolfgang Goethe-University, Frankfurt, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Akoglu
authors.forename: M
authors.initials: M
authors.lastname: Schrott
authors.forename: H
authors.initials: H
authors.lastname: Bolouri
authors.forename: A
authors.initials: A
authors.lastname: Jaffari
authors.forename: E
authors.initials: E
authors.lastname: Kutschera
authors.forename: W F
authors.initials: WF
authors.lastname: Caspary
authors.forename: D
authors.initials: D
authors.lastname: Faust
mesh_terms: D002851:Chromatography, High Pressure Liquid; D019587:Dietary Supplements; D004311:Double-Blind Method; D005260:Female; D005492:Folic Acid / Q000378:metabolism / Q000627:therapeutic use*; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000188:drug therapy*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013763:Tetrahydrofolates / Q000378:metabolism / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D013763:Tetrahydrofolates; D006710:Homocysteine; D005492:Folic Acid; C005984:5-methyltetrahydrofolate